InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

Current share price for CUV : $7.120 0.05 (0.71%)+

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$359 CLINUVEL strategic reorganisation to refocus on U.S. markets 23 Jul 2026 9:11AM $9.880 $7.120 fallen by 27.94%
$359 CLINUVEL's ADS commences trading on Nasdaq 21 Jul 2026 8:35AM $10.240 $7.120 fallen by 30.47%
$359 CLINUVEL's ADS to commence trading on Nasdaq 20 Jul 2026 8:33AM $9.920 $7.120 fallen by 28.23%
$359 SCENESSE approved for EPP in Canada 13 Jul 2026 8:34AM $10.270 $7.120 fallen by 30.67%
$359 CLINUVEL confirms terms of CEO's Employment Agreement 2 Jul 2026 11:36AM $10.350 $7.120 fallen by 31.21%
$359 CLINUVEL publicly files 20-F to U.S. SEC 16 Jun 2026 9:06AM $9.250 $7.120 fallen by 23.03%
$359 CLINUVEL US Non-Deal Roadshow Presentation 2 Jun 2026 9:26AM $9.260 $7.120 fallen by 23.11%
$359 Notification regarding unquoted securities - CUV 7 May 2026 11:45AM $9.490 $7.120 fallen by 24.97%
$359 CLINUVEL update on Level II ADR upgrade, Nasdaq uplist 28 Apr 2026 8:50AM $8.980 $7.120 fallen by 20.71%
$359 FDA relaxes SCENESSE postmarketing requirement 27 Apr 2026 8:42AM $9.040 $7.120 fallen by 21.24%
$359 Final EMA scientific advice for pivotal Phase III vitiligo 24 Apr 2026 8:56AM $8.810 $7.120 fallen by 19.18%
$359 Notification of cessation of securities - CUV 17 Apr 2026 9:04AM $9.230 $7.120 fallen by 22.86%
$359 Section 708A Cleansing Statement 13 Apr 2026 8:50AM $9.090 $7.120 fallen by 21.67%
$359 Application for quotation of securities - CUV 13 Apr 2026 8:49AM $9.090 $7.120 fallen by 21.67%
$359 Change in substantial holding 13 Apr 2026 8:18AM $9.090 $7.120 fallen by 21.67%
$359 CLINUVEL reports highlights from AAD 2026 2 Apr 2026 12:15PM $9.250 $7.120 fallen by 23.03%
$359 CLINUVEL's global programs showcased at AAD 27 Mar 2026 8:35AM $9.780 $7.120 fallen by 27.20%
$359 Chair Letter to Shareholders 20 Mar 2026 8:30AM $9.470 $7.120 fallen by 24.82%
$359 CLINUVEL Investor Webinar Half Year Results December 2025 5 Mar 2026 9:48AM $9.610 $7.120 fallen by 25.91%
$359 Half Year Results Presentation 26 Feb 2026 9:58AM $11.410 $7.120 fallen by 37.60%
$359 CLINUVEL Record Revenues, Advances Strategic Expansion 26 Feb 2026 9:55AM $11.410 $7.120 fallen by 37.60%
$359 Appendix 4D and Half Year Report 26 Feb 2026 9:54AM $11.410 $7.120 fallen by 37.60%
$359 CLINUVEL Investor Webinar 19 Feb 2026 9:04AM $11.020 $7.120 fallen by 35.39%
$359 Clinical & Financial Update 2 Feb 2026 8:30AM $11.000 $7.120 fallen by 35.27%
$359 Managing Director Letter to Shareholders 15 Jan 2026 9:11AM $12.230 $7.120 fallen by 41.78%

26 - 50 of 881 results

Page 2 of 36

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.